BioNTech SE (NASDAQ:BNTX) Short Interest Up 22.3% in November

BioNTech SE (NASDAQ:BNTX) was the recipient of a large growth in short interest in the month of November. As of November 15th, there was short interest totalling 2,470,000 shares, a growth of 22.3% from the October 31st total of 2,020,000 shares. Based on an average daily trading volume, of 1,120,000 shares, the days-to-cover ratio is presently 2.2 days.

Wall Street Analyst Weigh In

Several research analysts have recently issued reports on the company. Evercore ISI raised BioNTech from an “in-line” rating to an “outperform” rating and upped their price objective for the stock from $110.00 to $125.00 in a research report on Tuesday, November 19th. Canaccord Genuity Group upped their price objective on BioNTech from $171.00 to $171.44 and gave the company a “buy” rating in a research note on Wednesday, November 27th. JPMorgan Chase & Co. reduced their price objective on BioNTech from $124.00 to $122.00 and set a “neutral” rating for the company in a research note on Tuesday, November 26th. Jefferies Financial Group raised BioNTech from a “hold” rating to a “buy” rating and upped their price objective for the company from $96.00 to $150.00 in a research note on Tuesday, September 17th. Finally, UBS Group upped their price objective on BioNTech from $97.00 to $131.00 and gave the company a “neutral” rating in a research note on Wednesday, September 18th. Four investment analysts have rated the stock with a hold rating, eleven have issued a buy rating and one has given a strong buy rating to the company. According to data from MarketBeat.com, the stock currently has a consensus rating of “Moderate Buy” and a consensus price target of $138.67.

BioNTech Trading Down 1.1 %

Shares of BNTX stock traded down $1.29 during mid-day trading on Monday, hitting $117.10. 313,511 shares of the company’s stock were exchanged, compared to its average volume of 813,673. BioNTech has a fifty-two week low of $76.53 and a fifty-two week high of $131.49. The stock has a 50-day simple moving average of $113.81 and a two-hundred day simple moving average of $98.77. The company has a quick ratio of 7.21, a current ratio of 7.33 and a debt-to-equity ratio of 0.01. The stock has a market cap of $28.07 billion, a price-to-earnings ratio of -56.68 and a beta of 0.26.

BioNTech (NASDAQ:BNTX) last issued its earnings results on Monday, November 4th. The company reported $0.81 earnings per share for the quarter, topping the consensus estimate of ($1.26) by $2.07. The business had revenue of $1.24 billion for the quarter, compared to analyst estimates of $514.08 million. BioNTech had a negative return on equity of 2.35% and a negative net margin of 15.16%. The business’s quarterly revenue was up 38.9% on a year-over-year basis. During the same period last year, the company posted $0.73 EPS. Equities analysts expect that BioNTech will post -3.72 EPS for the current fiscal year.

Institutional Trading of BioNTech

Several large investors have recently modified their holdings of BNTX. GAMMA Investing LLC grew its stake in BioNTech by 86.9% in the second quarter. GAMMA Investing LLC now owns 512 shares of the company’s stock worth $41,000 after purchasing an additional 238 shares in the last quarter. EverSource Wealth Advisors LLC grew its holdings in shares of BioNTech by 106.3% during the first quarter. EverSource Wealth Advisors LLC now owns 489 shares of the company’s stock valued at $43,000 after purchasing an additional 252 shares during the last quarter. Planning Capital Management Corp raised its position in shares of BioNTech by 45,000.0% during the 3rd quarter. Planning Capital Management Corp now owns 451 shares of the company’s stock worth $54,000 after purchasing an additional 450 shares during the period. Blue Trust Inc. lifted its holdings in shares of BioNTech by 491.1% in the 3rd quarter. Blue Trust Inc. now owns 467 shares of the company’s stock worth $55,000 after purchasing an additional 388 shares during the last quarter. Finally, Daiwa Securities Group Inc. grew its stake in BioNTech by 430.3% during the 2nd quarter. Daiwa Securities Group Inc. now owns 1,925 shares of the company’s stock worth $155,000 after buying an additional 1,562 shares during the last quarter. 15.52% of the stock is currently owned by institutional investors and hedge funds.

About BioNTech

BioNTech SE, a biotechnology company, develops and commercializes immunotherapies for cancer and other infectious diseases. The company is developing FixVac product candidates, including BNT111, which is in Phase II clinical trial for advance melanoma; BNT112 that is in Phase I/IIa clinical trial for prostate cancer; BNT113, which is in Phase II clinical trial to treat HPV 16+ head and neck cancers; BNT114 to treat triple negative breast cancer; BNT115, which is in Phase I clinical trial in ovarian cancer; and BNT116, which is in Phase I clinical trial for non-small cell lung cancer.